Wspolczesna Onkologia-Contemporary Oncology最新文献

{"title":"Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies.","authors":"Aleksandra Mechlińska, Katarzyna Frąckiewicz, Katarzyna Gładyś-Cieszyńska, Dagmara Buczek, Rafał Dziadziuszko","doi":"10.5114/wo.2025.148643","DOIUrl":"https://doi.org/10.5114/wo.2025.148643","url":null,"abstract":"<p><p>Small intestinal bacterial overgrowth (SIBO) is defined by an abnormal proliferation of colon-specific bacteria in the small intestine, whereas intestinal methanogen overgrowth (IMO) manifests with an increase of methane-producing archaea, specifically Methanobrevibacter smithii. Both conditions can disrupt gastrointestinal motility and manifest with various clinical symptoms. Small intestinal bacterial overgrowth appears to increase the risk of malnutrition and negatively affect malabsorption of essential nutrients such as vitamin B₁₂ and fat-soluble vitamins. This concern is particularly relevant for cancer patients as malnutrition can adversely affect treatment outcomes and mortality rates. Small intestinal bacterial overgrowth prevalence is 2.5-22% in the general population, with significantly higher rates observed in cancer patients, depending on a study, 65% of gastric and colorectal cancer patients, 63.3% of pancreatic cancer patients compared to 13.3% in healthy controls. Gastrointestinal complications, particularly in cases of gastrointestinal cancers, can arise from both the disease itself and its treatment. Managing symptoms becomes more challenging when SIBO occurs as its symptoms are often ambiguous and overlap with those of other conditions. This review summarizes the current state of knowledge on SIBO and IMO in gastrointestinal cancers. Current knowledge on SIBO and IMO, particularly in gastrointestinal cancer, is limited by the lack of validated diagnostic standards, evidence-based nutritional guidelines, and a focus on symptom control rather than underlying mechanisms. There is a need for research on recurrence despite treatment, as well as studies specifically targeting SIBO and IMO in cancer rather than as comorbidities. Future efforts should prioritize developing reliable diagnostics, understanding recurrence mechanisms, and exploring personalized therapies and nutritional interventions.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"11-21"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic analysis reveals potential biomarker candidates in serous ovarian tumors - a preliminary study.","authors":"Shona Pedersen, Alaaeldin Ali Mohamed, Hubert Krzyslak, Latifa Saad S A Al-Kaabi, Mohannad Natheef Abuhaweeleh, Ala-Eddin Al Moustafa, Lina Ghabreau, Semir Vranic, Bent Honoré","doi":"10.5114/wo.2025.149180","DOIUrl":"https://doi.org/10.5114/wo.2025.149180","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian serous cystadenocarcinoma (SCA), a deadly gynecologic cancer, often goes undetected until the late stages. Tissue proteomics unveils disease heterogeneity, enhancing tumor classification and enabling personalized treatments tailored to individual expression profiles.</p><p><strong>Material and methods: </strong>Tissue samples from 46 serous ovarian tumors were quantified using label-free liquid chromatography-tandem mass spectrometry. We identified 80 proteins differentiating SCA from borderline tumors, 277 distinguishing SCA from benign tumors, and 195 between borderline and benign tumors. Ingenuity pathway analysis revealed increased cell proliferation and RNA processing in SCA and borderline tumors compared to benign tumors, with SCA showing greater oxidative phosphorylation than borderline tumors.</p><p><strong>Results: </strong>Our comparative analysis indicates that upregulated (ASS1 - argininosuccinate synthase 1, CAPS, PPA1, BCAT1, MCM4) and downregulated proteins (MUC5B, SLC4A1, tenascin-XB - TNXB, carbonic anhydrase 1, hemoglobin β) may offer a robust panel for distinguishing SCA from benign and borderline ovarian tumors, potentially aiding in early diagnosis and disease monitoring. The cancer-associated proteins pyridoxal dependent decarboxylase domain containing 1 (AUC: 0.83, 95% CI: 0.66-1), GFPT1 (AUC: 0.84, CI: 0.70-0.89), and HYOU1 (AUC: 0.84, CI: 0.70-0.98) significantly differentiated between low-grade (LGSCA) and high-grade serous cystadenocarcinoma (HGSCA). Low-grade SCA showed significantly greater levels of MZB1 (log₂ fold change (FC): -1.951, <i>p</i>-value: 0.0258), CRABP2 (FC: -2.34, <i>p</i>-value: 0.0016), and BCAM (FC: -1.945, <i>p</i>-value: 0.0197) than borderline cancers.</p><p><strong>Conclusions: </strong>Argininosuccinate synthase 1 and TNXB showed potential as markers of disease progression. Elevated ASS1 was observed in borderline, LGSCA, and HGSCA tumors compared to benign tumors, while TNXB levels progressively declined from benign to borderline, LGSCA, and HGSCA tumors. Our study pinpoints critical biomarkers in serous ovarian tumors for HGSCA progression.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"77-92"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated lactate dehydrogenase in adjuvant BRAF and MEK inhibitor therapy does not have diagnostic significance in detecting melanoma recurrence.","authors":"Łukasz Galus, Daria Tusień-Małecka, Jacek Mackiewicz","doi":"10.5114/wo.2025.149038","DOIUrl":"https://doi.org/10.5114/wo.2025.149038","url":null,"abstract":"<p><strong>Introduction: </strong>Lactate dehydrogenase (LDH) is an intracellular enzyme the concentration of which in the serum of melanoma patients is a commonly used biomarker for detecting recurrence, monitoring the effectiveness of ongoing systemic treatment, and for determination of prognosis.</p><p><strong>Material and methods: </strong>In this report we evaluated the clinical value of elevated LDH during adjuvant BRAF (dabrafenib) and MEK (trametinib) inhibitors in 23 patients after resection of stage III cutaneous, <i>BRAF</i>-mutated melanoma.</p><p><strong>Results: </strong>The treatment was administered for one year or until disease progression or unactable toxicity. In all patients, an increase in LDH was observed during treatment, of whom 18 patients had an increase to values above the upper limit of normal, while 4 patients had an increase within normal limits. After discontinuation of dabrafenib with trametinib, a decrease in LDH levels was observed in all patients except one, in whom treatment was discontinued due to disease progression. The increase in LDH was not associated with disease progression. Hypotheses explaining the increase in LDH include, among others, the immunomodulatory effect of BRAF and MEK inhibitors and the effect of drugs in question on the MAPK pathway in wild-type <i>BRAF</i> cells.</p><p><strong>Conclusions: </strong>Information on the common increase in LDH in patients undergoing adjuvant therapy with dabrafenib with trametinib will avoid additional imaging studies in many situations and may prevent unnecessary emotional stress for patients.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"107-112"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of interleukin-6 classic and trans-signaling and interleukin-11 classic signaling in gastric cancer cells.","authors":"Josephine Runge, Christoph Garbers, Juliane Lokau","doi":"10.5114/wo.2024.142211","DOIUrl":"https://doi.org/10.5114/wo.2024.142211","url":null,"abstract":"<p><strong>Introduction: </strong>The cytokine interleukin-11 (IL-11) binds on its target cells to a membrane-bound IL-11R, which results in homodimerization of the signal-transducing β-receptor gp130. Recent studies have uncovered a pro- inflammatory role in several diseases, including different tumor entities, and mouse models have revealed a crucial role of the IL-11/IL-11R axis in gastric cancer. However, studies regarding human gastric cancer are sparse, and whether the results obtained in mouse models also hold true in the human situation is little investigated.</p><p><strong>Material and methods: </strong>We analyzed gene expression of <i>IL11RA, IL11, IL6R, IL6</i> and <i>IL6ST</i> in different gastric tumor and immune cell lines. Furthermore, we stimulated these cell lines with exogenous cytokines and determined intracellular signaling. Finally, we analyzed gene expression data of gastric tumor patients and correlated them with overall patient survival.</p><p><strong>Results: </strong>This study showed that different gastric tumor cell lines respond to IL-6 classic and trans-signaling, but only slightly to stimulation with IL-11. We observed that monocyte-like cell lines expressed high levels of IL-6R and responded to IL-6, but not to stimulation with IL-11. Using gene expression data, we found that <i>IL11RA</i> and <i>IL11</i> are not overexpressed in human gastric cancer tissue and do not correlate with patient survival. However, low <i>IL6</i> expression is associated with higher overall survival.</p><p><strong>Conclusions: </strong>We provided evidence for IL-6 but not IL-11 signaling in gastric tumor cells and demonstrated that <i>IL6</i> expression in gastric tumors is associated with overall survival of patients.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 2","pages":"105-113"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological distress and coping strategies in parents of children receiving cancer therapy in Morocco - a correlational study.","authors":"Asmaa Marrakchi, Miloud Chakit, Naoual Elmorabit, Maria El Kababri, Aboubaker El Hessni, Abdelhalim Mesfioui","doi":"10.5114/wo.2024.144134","DOIUrl":"https://doi.org/10.5114/wo.2024.144134","url":null,"abstract":"<p><strong>Introduction: </strong>Treating a child with cancer in a family is a challenge that can have an impact on mental health. The study consists of determining the prevalence of psychological distress of parents of cancer children and exploring its correlations with their coping strategies.</p><p><strong>Material and methods: </strong>The survey was conducted between March and July 2023 among parents or guardians of children with cancer. The data collection tool was a version of the general health questionnaire (GHQ12) to estimate the prevalence of psychological distress and the coping orientation to problems experienced, to explore coping strategies. The correlation between the mean GHQ12 score and adaptation strategies is assessed through bivariate analyses and multiple regression.</p><p><strong>Results: </strong>232 parents or guardians of children participated in the study. The average GHQ12 score (0-36) was 22 ±6.83. Regarding coping strategies, religion was the most frequently used strategy. The general health questionnaire score showed significant negative correlations with active coping strategies with <i>r</i> = -0.14; <i>p</i> = 0.03, and acceptance with <i>r</i> = -0.51; <i>p</i> < 0.001, and significant positive correlations with denial with <i>r</i> = 0.25; <i>p</i> < 0.001, and self-blame with <i>r</i> = 0.24; <i>p</i> < 0,001. In multivariate analysis, acceptance (β = -1.9, <i>p</i> < 0.001) and denial stra- tegy (β = 0.46, <i>p</i> = 0.02) are predictive factors of psychological distress.</p><p><strong>Conclusions: </strong>The study highlights the significant impact of coping strategies on the psychological distress experienced by parents of children undergoing cancer treatment in Morocco, by facilitating a more resilient adaptation and improved psychological well-being. These findings could form the basis for the development of culturally adapted mental health support programs for parents in simi-lar contexts.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 3","pages":"260-266"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep feature extraction and fine κ-nearest neighbour for enhanced human papillomavirus detection in cervical cancer - a comprehensive analysis of colposcopy images.","authors":"Lipsarani Jena, Santi Kumari Behera, Srikanta Dash, Prabira Kumar Sethy","doi":"10.5114/wo.2024.139091","DOIUrl":"10.5114/wo.2024.139091","url":null,"abstract":"<p><strong>Introduction: </strong>This study introduces a novel methodology for classifying human papillomavirus (HPV) using colposcopy images, focusing on its potential in diagnosing cervical cancer, the second most prevalent malignancy among women globally. Addressing a crucial gap in the literature, this study highlights the unexplored territory of HPV-based colposcopy image diagnosis for cervical cancer. Emphasising the suitability of colposcopy screening in underdeveloped and low-income regions owing to its small, cost-effective setup that eliminates the need for biopsy specimens, the methodological framework includes robust dataset augmentation and feature extraction using EfficientNetB0 architecture.</p><p><strong>Material and methods: </strong>The optimal convolutional neural network model was selected through experimentation with 19 architectures, and fine-tuning with the fine κ-nearest neighbour algorithm enhanced the classification precision, enabling detailed distinctions with a single neighbour.</p><p><strong>Results: </strong>The proposed methodology achieved outstanding results, with a validation accuracy of 99.9% and an area under the curve (AUC) of 99.86%, with robust performance on test data, 91.4% accuracy, and an AUC of 91.76%. These remarkable findings underscore the effectiveness of the integrated approach, which offers a highly accurate and reliable system for HPV classification.Conclusions: This research sets the stage for advancements in medical imaging applications, prompting future refinement and validation in diverse clinical settings.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 1","pages":"37-44"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of patients treated for stage IV breast cancer. Multidimensional assessment and examination of determining factors.","authors":"Juan Ignacio Arraras, Jose Juan Illarramendi, Ana Manterola, Uxue Zarandona, Berta Ibañez, Andrew Bottomley, Lucia Teijeira, Ignacio Visus, Susana de la Cruz, Marta Barrado, Ruth Vera","doi":"10.5114/wo.2024.147006","DOIUrl":"10.5114/wo.2024.147006","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic breast cancer (MBC) can profoundly impact patients' lives. The health-related quality of life (HRQOL) of MBC metavivors remains a paramount concern. This study exa-mined the multifaceted aspects of HRQOL in MBC metavivors.</p><p><strong>Material and methods: </strong>Ninety-eight participants with over 4 years of meta-static disease were evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) questionnaires QLQ-C30, QLQ-BR42 and QLQ-BM22 alongside the Assessment of Survivor Concerns (ASC) questionnaire.</p><p><strong>Results: </strong>HRQOL scores were high (> 80/100 points) in some HRQOL areas, including role, cognitive and social functioning and breast symptoms. Moderate limitations (> 30 points) occurred in global QOL and financial impact (QLQ-C30); sexual functioning, sexual enjoyment, future perspective, breast satisfaction, upset by hair loss, skeletal symptoms, and weight gain (QLQ-BR42); and psychosocial aspects of QLQ-BM22. Worries were moderate in the two ASC factors (6.8 and 5.3) and the global scale (11.7). The multivariate model that best explains high risk of low global QOL included limiting comorbidity, financial impact, cancer worry and role functioning (<i>R</i> ² = 0.692). Patients with only bone metastases showed higher cancer and health worries (ASC scale) than patients with soft tissues and visceral sites.</p><p><strong>Conclusions: </strong>This study shows that MBC metavivors adapted well to their situation and underscores the persistent HRQOL challenges they face. In-depth analysis of the QLQ-C30 glo-bal score highlights the need to address not only medical aspects but also integrated psychosocial and economi-cal support in MBC metavivor care. HRQOL variations across metastatic sites underscore the need to tailor interventions to address site-specific challenges.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 4","pages":"350-357"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of selected circulating cytokines from the IL-6 family - interleukin 6, oncostatin M, and cardiotrophin-1 - in gastro-entero-pancreatic and bronchial neuroendocrine tumours.","authors":"Janusz Strzelczyk, Ksenia Janas, Joanna Katarzyna Strzelczyk, Elżbieta Chełmecka, Dariusz Kajdaniuk, Beata Kos-Kudła","doi":"10.5114/wo.2024.142584","DOIUrl":"https://doi.org/10.5114/wo.2024.142584","url":null,"abstract":"<p><strong>Introduction: </strong>The incidence of neuroendocrine tumours (NETs) increased over the last years. Most of them are non-functioning, and the course of the disease is asymptomatic for a long time. This results in late diagnosis at an advanced stage. The aim of our study was the evaluation of selected circulating cytokines of interleukin-6 family - interleukin 6 (IL-6), oncostatin M (OSM), and cardiotrophin-1 (CT1) - in NETs.</p><p><strong>Material and methods: </strong>The study group comprised 80 patients (56%) in several subgroups, including gastroenteropancreatic (GEPNETs, <i>n</i> = 64, 80%) and bronchopulmonary neuroendocrine tumours (BPNETs, <i>n</i> = 16; 20%). Serum IL-6, OSM, and CT1 concentrations were tested using ELISA.</p><p><strong>Results: </strong>The median concentration of IL-6 was 41.5 pg/ml in the study group and 32.6 pg/ml in the control group, and the difference was statistically significant (<i>p</i> < 0.001). The concentration of OSM was significantly lower in the study group than in the control group (<i>p</i> < 0.001), at 105.6 pg/ml and 115.5 pg/ml, respectively. There was a significant difference (<i>p</i> < 0.01) in concentration of CT1 in the study group (222.0 pg/ml) and controls (267.2 pg/ml). Our investigation into selected IL-6 family cytokines revealed differential modulation of signal transduction pathways.</p><p><strong>Conclusions: </strong>These findings suggest that despite utilising a common signalling transducer, individual IL-6 family cytokines exert distinct biological effects on neuroendocrine tumour development. Notably, IL-6 appears to promote tumourigenesis, while OSM and CT1 exhibit inhibitory effects on gastro-entero-pancreatic and bronchial neuroendocrine tumour development. Further studies are necessary to validate the diagnostic utility of IL-6 family cytokines in NETs.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 2","pages":"114-120"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes of patients with BRAF^V600E-mutated metastatic colorectal cancer: a Polish retrospective cohort study.","authors":"Jolanta Żok, Michał Bieńkowski, Barbara Radecka, Agata Kuchar, Szymon Borowiec, Joanna Streb, Michał Jurczyk, Anna Jakieła-Drąg, Marek Gełej, Patryk Zając, Małgorzata Ploch-Glapińska, Renata Duchnowska","doi":"10.5114/wo.2024.146953","DOIUrl":"10.5114/wo.2024.146953","url":null,"abstract":"<p><strong>Introduction: </strong>The BRAF^V600E mutation is found in 6-11% of metastatic colo-rectal cancer (mCRC) patients. According to international guidelines for BRAF^V600E-mutated mCRC, the triplet chemotherapy FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) or double chemotherapy with or without bevacizumab, and encorafenib plus cetuximab should be considered in the first- and second-line settings. We aimed to evaluate clinical practices in BRAF^V600E-mutated mCRC patients treated at five Polish oncology centers.</p><p><strong>Material and methods: </strong>We retrospectively analyzed the data of BRAF^V600E- mutated mCRC patients treated between 2011 and 2023. Before starting the first-line treatment, all patients were tested for BRAF and RAS mutations.</p><p><strong>Results: </strong>One hundred twenty-six patients (median age: 68 years; 55% female, 45% male) from five oncology centers were included. The majority of patients (69, 55%) had a right-sided primary tumor. The first line of chemotherapy was received by 100 patients (79.4%). The majority received doublet chemotherapy: FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin), FOLFIRI (folinic acid, 5-fluorouracil, irinotecan), XELOX (capecitabine, oxaliplatin), and FOLFIRI with bevacizumab: 30 (30%), 47 (47%), 5 (5%), and 3 (3%). Only three patients received FOLFOXIRI; one patient received bevacizumab. The median duration of first-line treatment was 5.26 months (95% CI: 0.03-18.9). Subsequently, 40%, 16%, 5%, and 1% of patients received second, third, fourth, and fifth-line therapy, retrospectively. During the median follow-up of 38.5 months, 96 (79.3%) patients died. The median overall survival from the time of mCRC diagnosis was 13.7 months (95% CI: 11.3-17.6).</p><p><strong>Conclusions: </strong>This study highlights the unmet need for effective treatment strategies for patients with BRAF^V600E-mutated mCRC in Poland.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 4","pages":"297-303"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting.","authors":"Carsten Nieder, Luka Stanisavljevic, Astrid Dalhaug, Ellinor Haukland","doi":"10.5114/wo.2024.138842","DOIUrl":"10.5114/wo.2024.138842","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate overall survival of men who received systemic therapy with docetaxel for metastatic castration- resistant prostate cancer (MCRPC) in rural Nordland County, Norway. Prognostic factors related to treatment and other variables were evaluated.</p><p><strong>Material and methods: </strong>Overall, 132 pa- tients were included in this retrospective study covering the years 2009-2022. Uni- and multivariate survival analyses were performed.</p><p><strong>Results: </strong>In this elderly cohort (median age 72 years), weekly low-dose docetaxel was the preferred regimen (44%). Seventy-three percent were treated in the first line. Only 11 patients (8%) were pre-exposed to docetaxel in the hormone-sensitive phase. Median survival was 14.3 months. Prognostic factors for longer survival included higher hemoglobin, lower lactate dehydrogenase, administration of docetaxel as first-line MCRPC treatment, and use of fewer prescription drugs for comorbidity. Pre-exposure to docetaxel did not play a major role, p = 0.76.</p><p><strong>Conclusions: </strong>In this rural health care setting, survival after docetaxel was shorter than reported by other groups. Blood test results were confirmed as important prognostic factors. In the present era of evolving treatment sequences, we recommend monitoring of real-world treatment results.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 1","pages":"31-36"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}